Advertisement
Mr. Laverty brings to Eisai more than 22 years of global corporate,product, policy and research and development communications experience in thepharmaceutical industry. Most recently, he served as Vice President, GlobalCommunications, Malaria Initiatives for Novartis AG, where he oversaw allglobal communications supporting the company's malaria initiative in thedeveloping world. In addition, Mr. Laverty has held several other executivetitles at Novartis Pharmaceuticals Corp, including Vice President, ExternalCommunication and Vice President, Global Pharma Media Relations.
Advertisement
Earlier in his career, Mr. Laverty held a number of progressivelyresponsible positions in corporate policy, corporate affairs, and productpublic affairs at Bristol-Myers Squibb Company. He holds a Bachelor ofScience degree in pharmacy from St. John's University, Jamaica, New York.
"Mr. Laverty is a welcome addition to our company and will be instrumentalin strengthening Eisai's visibility and presence in the U.S. as a top-20pharmaceutical company," said Lonnel Coats, President & COO, Eisai Corporationof North America. "With his more than two decades of senior communicationsexpertise in the global pharmaceutical industry, Mr. Laverty's contributionsto our company will be invaluable, as we continue to fulfill our human healthcare (hhc) mission to satisfy unmet medical needs and increase benefits topatients and their families."
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of EisaiCo., Ltd. and supports the activities of its operating companies in NorthAmerica. These operating companies include: Eisai Research Institute ofBoston, Inc., a discovery operation with strong organic chemistrycapabilities; Morphotek, Inc., a biopharmaceutical company specializing in thedevelopment of therapeutic monoclonal antibodies; Eisai Medical Research Inc.,a clinical development group; Eisai Inc., a commercial operation withmanufacturing and marketing/sales functions; MGI PHARMA, Inc., an R&D andcommercial operation with manufacturing and marketing/sales functions; andEisai Machinery U.S.A., which markets and maintains pharmaceuticalmanufacturing machinery. For more information about Eisai, please visitwww.eisai.com.
SOURCE Eisai Corporation of North America
